Sasamori Toru, Hida Kazutoshi, Yano Shunsuke, Asano Takeshi, Seki Toshitaka, Houkin Kiyohiro
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, North-15 West-7, Kita-ku, Sapporo, 060-8638, Japan.
Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan.
Eur Spine J. 2016 Mar;25(3):748-54. doi: 10.1007/s00586-015-3887-0. Epub 2015 Mar 24.
To examine the validity of our treatment strategy for spinal dural arteriovenous fistulae (SDAVF), based on the treatment results and the long-term outcome.
This study included 50 SDAVF patients (38 men, 12 women, mean age 63.2 years) with progressive myelopathy. The treatment strategy involved embolization as the initial management tool and surgery if embolization was considered unsuitable. Their medical records were evaluated to identify the treatment results and functional outcomes. The mean follow-up period was 81.2 months (range 27-184 months).
Complete obliteration was achieved in 22 (71.0%) of 31 embolized patients and in 18 of 19 (94.7%) operated patients. The initial success rate was significantly lower in embolized than operated patients. At the last follow-up, 33 of the 50 patients (66%) manifested improved gait and 16 (32%) improved micturition. The activity of daily living (ADL) was improved in 33 (66%). When we compared the rates of functional improvement at the last follow-up, there was no significant difference between patients treated initially by embolization or surgery.
The long-term outcomes in SDAVF patients treated by multidisciplinary management with first-line embolization were comparable to those in earlier surgical series. However, our results were unable to demonstrate the superiority of endovascular embolization to surgical treatment for SDAVF. For the purpose of justifying endovascular embolization as a first-line treatment for SDAVF, it will be necessary to show further improvement in both the initial treatment success and the complication rates.
基于治疗结果和长期预后,检验我们针对脊髓硬脊膜动静脉瘘(SDAVF)的治疗策略的有效性。
本研究纳入了50例患有进行性脊髓病的SDAVF患者(38例男性,12例女性,平均年龄63.2岁)。治疗策略包括将栓塞作为初始治疗手段,若认为栓塞不合适则进行手术。对他们的病历进行评估以确定治疗结果和功能预后。平均随访期为81.2个月(范围27 - 184个月)。
31例接受栓塞治疗的患者中有22例(71.0%)实现完全闭塞,19例接受手术治疗的患者中有18例(94.7%)实现完全闭塞。栓塞治疗患者的初始成功率显著低于手术治疗患者。在最后一次随访时,50例患者中有33例(66%)步态改善,16例(32%)排尿改善。33例(66%)患者的日常生活活动(ADL)得到改善。当我们比较最后一次随访时的功能改善率时,最初接受栓塞或手术治疗的患者之间没有显著差异。
采用一线栓塞的多学科管理方法治疗的SDAVF患者的长期预后与早期手术系列的预后相当。然而,我们的结果未能证明血管内栓塞治疗SDAVF优于手术治疗。为了证明血管内栓塞作为SDAVF一线治疗方法的合理性,有必要在初始治疗成功率和并发症发生率方面进一步改善。